Kennedy Ferruggia, Associate Editor

Coinfection with RSV and hRV is linked to a higher prevalence of lower respiratory tract infections, according to new data.

Phil Vigeant shares insights on the health benefits of protein supplements and guidance for consumers to identify safe and effective protein powder products.

Invasive meningococcal disease is a severe bacterial infection caused by the bacterium Neisseria meningitidis, often leading to meningitis or sepsis.

RSV poses a significant threat to high-risk adults, but effective vaccines offer strong protection, highlighting the need for increased vaccination rates and education.

Insulin-aspart-szjj (Merilog) is the first rapid-acting insulin biosimilar product approved by the FDA.

Treatment with 2.4 mg of semaglutide did not increase the risk of developing suicidal ideation or behavior compared with placebo.

Diabetes management through insulin could play a significant role in preventing antibiotic resistance.

Risdiplam is the only approved non-invasive disease-modifying SMA treatment.

Duloxetine offers treatment for various neuro-psychiatric and pain disorders in patients who have difficulty swallowing.

Amazon Pharmacy’s subscription service could cause sale disruptions for traditional retail pharmacies.

Pharmacists can recommend vitamin D supplements and vitamin D-rich foods to support healthy pregnancy outcomes.

If approved, HLX11 could offer a more cost-effective alternative to pertuzumab for the treatment of human epidermal growth factor receptor 2-positive breast cancer.

New therapies are being developed for individuals with gout.

ABO-101 is supported by preclinical data that demonstrated significant reductions in urinary oxalate in PH1 disease models.

Encorafenib in combination with cetuximab and mFOLFOX6 met its dual primary end point of overall response rate of 61%.

Nivolumab plus ipilimumab demonstrated a 38% reduction in the risk of disease progression or death.

Investigators found that 60% of individuals with type 2 diabetes are vitamin D deficient.

Tocilizumab-anoh is expected to increase competition, improve patient access, and deliver cost savings in the treatment of various inflammatory conditions.

S-337395 demonstrated an 88.4% reduction in viral load and had a statistically significant improvement in clinical symptoms scores.

Lu-edotreotide (ITM-11; ITM) met its primary endpoint of prolonging progression-free survival (PFS).

The supplemental new drug application is based on objective response rate and duration of response results from a phase 2 study that assessed the efficacy and safety of belzutifan.

This marks the first US biologic license application filing acceptance for a biosimilar candidate to golimumab.

MB-105 is a first-in-class CD5-targeted chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed or refractory CD5-positive T-cell lymphoma.

The trial meets one of the study’s dual primary endpoints of progression-free survival, but did not meet its other primary endpoint of overall survival.

The cobas liat system is a closed system that aims to reduce contamination risks and enhances the reliability of results at the point of care.

Antiviral treatments for respiratory viruses such as respiratory syncytial virus (RSV) are crucial, especially with the rise of the "triple-demic."

Boosting ursodeoxycholic acid (UDCA) levels through dietary supplementation was shown to control tumor growth in mice with liver cancer.

Biosimilar use is not linked to an increased risk of treatment failure among pediatric patients with inflammatory bowel disease (IBD).

Point-of-care testing implementation could provide valuable data on community respiratory syncytial virus incidence and enhance sentinel surveillance efforts.

The fast-track designation follows the FDA orphan drug designation that was granted for DYNE-101 in September 2023 for the same treatment population.